MX2014008705A - Compuestos tricíclicos de sulfona y métodos para elaborarlos y utilizarlos. - Google Patents

Compuestos tricíclicos de sulfona y métodos para elaborarlos y utilizarlos.

Info

Publication number
MX2014008705A
MX2014008705A MX2014008705A MX2014008705A MX2014008705A MX 2014008705 A MX2014008705 A MX 2014008705A MX 2014008705 A MX2014008705 A MX 2014008705A MX 2014008705 A MX2014008705 A MX 2014008705A MX 2014008705 A MX2014008705 A MX 2014008705A
Authority
MX
Mexico
Prior art keywords
methods
making
same
sulfone compounds
tricyclic
Prior art date
Application number
MX2014008705A
Other languages
English (en)
Spanish (es)
Inventor
Robert Zahler
Hazel Joan Dyke
Thomas David Pallin
Susan Mary Cramp
Original Assignee
Zafgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zafgen Inc filed Critical Zafgen Inc
Publication of MX2014008705A publication Critical patent/MX2014008705A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/94—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
MX2014008705A 2012-01-18 2013-01-17 Compuestos tricíclicos de sulfona y métodos para elaborarlos y utilizarlos. MX2014008705A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261587825P 2012-01-18 2012-01-18
PCT/US2013/021914 WO2013109735A1 (en) 2012-01-18 2013-01-17 Tricyclic sulfone compounds and methods of making and using same

Publications (1)

Publication Number Publication Date
MX2014008705A true MX2014008705A (es) 2015-02-05

Family

ID=47710307

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014008705A MX2014008705A (es) 2012-01-18 2013-01-17 Compuestos tricíclicos de sulfona y métodos para elaborarlos y utilizarlos.

Country Status (10)

Country Link
US (1) US9440943B2 (enExample)
EP (1) EP2804856B1 (enExample)
JP (1) JP2015509102A (enExample)
KR (1) KR20140112566A (enExample)
CN (1) CN104169268A (enExample)
AU (1) AU2013209719A1 (enExample)
BR (1) BR112014017780A8 (enExample)
CA (1) CA2861381A1 (enExample)
MX (1) MX2014008705A (enExample)
WO (1) WO2013109735A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013055385A2 (en) 2011-10-03 2013-04-18 Zafgen Corporation Methods of treating age related disorders
WO2011085198A1 (en) 2010-01-08 2011-07-14 Zafgen Corporation Metap-2 inhibitor for use in treating benign prostatic hypertrophy (bph)
WO2011127304A2 (en) 2010-04-07 2011-10-13 Zafgen Corporation Methods of treating an overweight subject
PH12013502261A1 (en) * 2011-05-06 2022-10-26 Zafgen Inc Partially saturated tricyclic compounds and methods of making and using same
AU2012253760B2 (en) 2011-05-06 2016-02-04 Zafgen, Inc. Tricyclic pyrazole sulfonamide compounds and methods of making and using same
WO2013109739A1 (en) 2012-01-18 2013-07-25 Zafgen, Inc. Tricyclic sulfonamide compounds and methods of making and using same
US9839622B2 (en) 2012-05-08 2017-12-12 Zafgen, Inc. Methods of treating hypothalamic obesity
JP6177888B2 (ja) 2012-05-09 2017-08-09 ザフゲン，インコーポレイテッド フマギロール型化合物ならびにその製造および使用方法
CN104870433A (zh) 2012-11-05 2015-08-26 扎夫根股份有限公司 三环化合物及其制备方法和用途
US9868717B2 (en) 2012-11-05 2018-01-16 Zafgen, Inc. Tricyclic sulphonamide compounds and methods of making and using same
JP6169716B2 (ja) 2012-11-05 2017-07-26 ザフゲン，インコーポレイテッド 肝疾患を治療する方法
AU2014236528A1 (en) 2013-03-14 2015-09-24 Zafgen, Inc. Methods of treating renal disease and other disorders
AR105671A1 (es) 2015-08-11 2017-10-25 Zafgen Inc Compuestos heterocíclicos de fumagillol y sus métodos de elaboración y uso
CN106432255A (zh) 2015-08-11 2017-02-22 扎夫根公司 烟曲霉素醇螺环化合物和制备和使用其的方法
PL3390355T3 (pl) * 2016-03-22 2023-05-02 Helsinn Healthcare S.A. Benzenosulfonylo-asymetryczne związki mocznikowe i ich zastosowania medyczne
CN107056742A (zh) * 2017-04-20 2017-08-18 牛永友 一种治疗哮喘的药物组合物
CN112898202B (zh) * 2021-01-27 2022-11-22 中国科学院上海有机化学研究所 一种杂环基并环丙烷化合物、合成方法

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5164410A (en) 1988-01-09 1992-11-17 Takeda Chemical Industries, Ltd. Fumagillol derivatives and pharmaceutical compositions thereof
PH26256A (en) 1988-08-12 1992-04-01 Fujisawa Pharmaceutical Co Oxaspiro [2,5] octane derivative
ES2099064T3 (es) 1988-09-01 1997-05-16 Takeda Chemical Industries Ltd Derivados de fumagillol.
US5180738A (en) 1988-09-01 1993-01-19 Takeda Chemical Industries Fumagillol derivatives and pharmaceutical compositions thereof
US5166172A (en) 1988-09-01 1992-11-24 Takeda Chemical Industries, Ltd. Fumagillol derivatives and pharmaceutical compositions thereof
US5288722A (en) 1989-03-06 1994-02-22 Takeda Chemical Industries, Ltd. 6-amino-6-desoxyfumagillols, production and use thereof
DE69001187T2 (de) 1989-03-06 1993-07-08 Takeda Chemical Industries Ltd 6-epifumagillole, ihre herstellung und ihre verwendung.
US6017954A (en) 1989-08-10 2000-01-25 Children's Medical Center Corp. Method of treating tumors using O-substituted fumagillol derivatives
US5290807A (en) 1989-08-10 1994-03-01 Children's Medical Center Corporation Method for regressing angiogenesis using o-substituted fumagillol derivatives
EP0415294A3 (en) 1989-08-31 1991-06-12 Takeda Chemical Industries, Ltd. Cyclohexanol derivatives, production and use thereof
TW282399B (enExample) 1990-05-25 1996-08-01 Takeda Pharm Industry Co Ltd
US5238950A (en) 1991-12-17 1993-08-24 Schering Corporation Inhibitors of platelet-derived growth factor
DE69330690T2 (de) 1992-01-30 2002-06-20 Takeda Chemical Industries, Ltd. Verfahren zur Herstellung hoch-wasserlöslicher Zyklodextrinkomplexe
ATE153854T1 (de) 1992-12-16 1997-06-15 Takeda Chemical Industries Ltd Stabile pharmazeutische zubereitung mit fumagillolderivaten
PL183378B1 (pl) 1995-03-27 2002-06-28 Assist Publ Hopitaux De Paris Zastosowanie fumagilolu i jego pochodnych do wytwarzania jelitowych środków przeciwinfekcyjnych
CA2234401A1 (en) 1995-10-11 1997-04-17 Fujisawa Pharmaceutical Co., Ltd. Vascular permeation inhibitor
EP0799616A1 (en) 1996-04-01 1997-10-08 Takeda Chemical Industries, Ltd. Oral composition comprising a fumagillol derivative
WO1998005293A2 (en) 1996-08-02 1998-02-12 The Children's Medical Center Corporation Method of regulating the female reproductive system through angiogenesis inhibitors
US6281245B1 (en) 1996-10-28 2001-08-28 Versicor, Inc. Methods for solid-phase synthesis of hydroxylamine compounds and derivatives, and combinatorial libraries thereof
CA2283145A1 (en) 1997-03-04 1998-09-11 Monsanto Company Aromatic sulfonyl alpha-hydroxy hydroxamic acid compounds
US7115632B1 (en) 1999-05-12 2006-10-03 G. D. Searle & Co. Sulfonyl aryl or heteroaryl hydroxamic acid compounds
US6207704B1 (en) 1997-06-09 2001-03-27 Massachusetts Institute Of Technology Type 2 methionine aminopeptidase [MetAP2] inhibitors and uses thereof
US6306819B1 (en) 1997-10-31 2001-10-23 Massachusetts Institute Of Technology Method for regulating size of vascularized normal tissue
JP2001526255A (ja) 1997-12-23 2001-12-18 ワーナー−ランバート・カンパニー 炎症性疾患およびアテローム性動脈硬化症を治療または予防するチオ尿素およびベンズアミド化合物、組成物並びに方法
US6242494B1 (en) 1998-05-01 2001-06-05 Abbott Laboratories Substituted β-amino acid inhibitors of methionine aminopeptidase-2
KR100357542B1 (ko) 1998-05-15 2002-10-18 주식회사종근당 푸마질롤 유도체 및 그 제조방법
KR100357541B1 (ko) 1998-05-15 2002-10-18 주식회사종근당 5-데메톡시 푸마질롤 유도체 및 그 제조방법
JP2000116337A (ja) 1998-10-09 2000-04-25 Nippon Shokuhin Kako Co Ltd ペットフード
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
CZ20013834A3 (cs) 1999-04-28 2002-04-17 Aventis Pharma Deutschland Gmbh Deriváty kyselin se třemi arylovými zbytky jako ligandy receptorů PPAR a farmaceutické prostředky, které je obsahují
CA2379342C (en) 1999-07-15 2007-01-02 Basf Aktiengesellschaft Process for the preparation of 5- and/or 6-substituted-2-hydroxybenzoic acid esters
JP2003510359A (ja) 1999-10-01 2003-03-18 スミスクライン・ビーチャム・コーポレイション 化合物および方法
US20020002152A1 (en) 2000-04-14 2002-01-03 Craig Richard A. Hydrazide and alkoxyamide angiogenesis inhibitors
US6323228B1 (en) 2000-09-15 2001-11-27 Abbott Laboratories 3-substituted indole angiogenesis inhibitors
AR030631A1 (es) 2000-09-29 2003-08-27 Abbott Lab Polipeptidos antiangiogenicos y metodos para inhibir la angiogenesis
WO2002042295A2 (en) 2000-11-01 2002-05-30 Praecis Pharmaceuticals Inc. Peptides as met-ap2 inhibitors
US6548477B1 (en) 2000-11-01 2003-04-15 Praecis Pharmaceuticals Inc. Therapeutic agents and methods of use thereof for the modulation of angiogenesis
CZ20031707A3 (cs) 2000-12-20 2003-11-12 Bristol-Myers Squibb Company Substituované pyrrodochinoliny a pyridochinoliny jako agonisté a antagonisté serotoninu
JP2004525942A (ja) 2001-03-29 2004-08-26 スミスクライン・ビーチャム・コーポレイション 化合物および方法
US20020183242A1 (en) 2001-04-11 2002-12-05 Jack Henkin Peptide antiangiogenic drugs
ATE440094T1 (de) 2001-09-27 2009-09-15 Equispharm Co Ltd Fumagillolderivate und verfahren zu deren herstellung
US6803382B2 (en) 2001-11-09 2004-10-12 Galderma Research & Development, S.N.C. Angiogenesis inhibitors and pharmaceutical and cosmetic use thereof
US7119120B2 (en) 2001-12-26 2006-10-10 Genzyme Corporation Phosphate transport inhibitors
KR100451485B1 (ko) 2002-03-28 2004-10-06 주식회사종근당 푸마질롤 유도체 또는 그 염의 포접 화합물, 및 이를포함하는 약제학적 조성물
US6989392B2 (en) 2002-06-18 2006-01-24 Abbott Laboratories 2-Aminoquinolines as melanin concentrating hormone receptor antagonists
US7030262B2 (en) 2002-08-06 2006-04-18 Abbott Laboratories 3-Amino-2-hydroxyalkanoic acids and their prodrugs
US20040067266A1 (en) 2002-10-07 2004-04-08 Toppo Frank R. Weight loss compound
US20040068012A1 (en) 2002-10-08 2004-04-08 Comess Kenneth M. Sulfonamides having antiangiogenic and anticancer activity
US7491718B2 (en) 2002-10-08 2009-02-17 Abbott Laboratories Sulfonamides having antiangiogenic and anticancer activity
US20040157836A1 (en) 2002-10-08 2004-08-12 Comess Kenneth M. Sulfonamides having antiangiogenic and anticancer activity
WO2004078113A2 (en) 2003-03-04 2004-09-16 Pharmacia Corporation Treatment and prevention of obesity with cox-2 inhibitors alone or in combination with weight-loss agents
DK1651621T3 (da) 2003-08-08 2008-11-10 Janssen Pharmaceutica Nv 2-(Quinoxalin-5-ylsulfonylamino)benzamidforbindelser som CCK2-modulatorer
TW200530157A (en) 2003-09-09 2005-09-16 Japan Tobacco Inc Dipeptidyl peptidase iv inhibitor
PT1697378E (pt) 2003-12-22 2008-02-28 Memory Pharm Corp Indoles, 1h-indazoles, 1,2-benzisoxazoles e 1,2-benzisotiazoles, sua preparação e utilizações
KR20060130077A (ko) 2003-12-29 2006-12-18 프래시스 파마슈티컬즈 인코포레이티드 메티오닌 아미노펩티다제-2 의 저해제 및 이의 용도
KR100552043B1 (ko) 2004-02-28 2006-02-20 주식회사종근당 푸마질롤 유도체를 포함하는 비만치료용 조성물
EP1748989A2 (en) 2004-05-12 2007-02-07 ChemoCentryx Inc Aryl sulfonamides
CA2571683A1 (en) 2004-06-30 2006-01-12 Combinatorx, Incorporated Methods and reagents for the treatment of metabolic disorders
US20060045865A1 (en) 2004-08-27 2006-03-02 Spherics, Inc. Controlled regional oral delivery
AU2005289887A1 (en) 2004-09-24 2006-04-06 Janssen Pharmaceutica, N.V. Sulfonamide compounds
CN101142210A (zh) 2005-01-26 2008-03-12 株式会社钟根堂 烟曲霉醇衍生物或制备烟曲霉醇衍生物的方法、以及包含该衍生物的药物组合物
FR2886855B1 (fr) 2005-06-08 2009-07-17 Agronomique Inst Nat Rech Utilisation de la fumagilline et de ses derives pour augmenter la biodisponibilite des lactones macrocyliques
US20070078172A1 (en) 2005-06-16 2007-04-05 Jenrin Discovery Mao-b inhibitors useful for treating obesity
ES2408318T3 (es) 2005-12-23 2013-06-20 Glaxosmithkline Llc Inhibidores de azaindol de las cinasas Aurora
US20100234364A1 (en) 2006-07-14 2010-09-16 Arindrajit Basak Ccr2 inhibitors and methods of use thereof
DE102007020492A1 (de) 2007-04-30 2008-11-06 Grünenthal GmbH Substituierte Sulfonamid-Derivate
EP2170402B1 (en) 2007-06-26 2015-03-25 Children's Medical Center Corporation Metap-2 inhibitor polymersomes for therapeutic administration
US20090011994A1 (en) 2007-07-06 2009-01-08 Bristol-Myers Squibb Company Non-basic melanin concentrating hormone receptor-1 antagonists and methods
JP5557746B2 (ja) 2007-11-28 2014-07-23 メルサナ セラピューティックス，インク． 生体適合性生分解性フマギリンアナログ複合体
HRP20110510T1 (hr) 2007-11-30 2011-08-31 Bayer Schering Pharma Aktiengesellschaft Heteroaril-supstituirani piperidini
AU2009270799B2 (en) 2008-07-18 2016-05-19 Zafgen, Inc. Methods of treating an overweight or obese subject
US8729097B2 (en) 2008-10-06 2014-05-20 The Johns Hopkins University Quinoline compounds as inhibitors of angiogenesis, human methionine aminopeptidase, and SIRT1, and methods of treating disorders
US8906896B2 (en) 2008-10-24 2014-12-09 Ulrich Bierbach Platinum acridine anti-cancer compounds and methods thereof
US20120010259A1 (en) 2008-12-04 2012-01-12 Vath James E Methods of Treating an Overweight or Obese Subject
WO2010065883A2 (en) * 2008-12-04 2010-06-10 Zafgen Corporation Method of treating an overweight or obese subject
US20120004162A1 (en) 2008-12-04 2012-01-05 Vath James E Methods of Treating an Overweight or Obese Subject
WO2010065879A2 (en) 2008-12-04 2010-06-10 Zafgen Corporation Methods of treating an overweight or obese subject
AU2010303270A1 (en) 2009-10-09 2012-05-03 Zafgen Corporation Sulphone compounds for use in the treatment of obesity
WO2011085198A1 (en) 2010-01-08 2011-07-14 Zafgen Corporation Metap-2 inhibitor for use in treating benign prostatic hypertrophy (bph)
WO2011088055A2 (en) 2010-01-12 2011-07-21 Zafgen Corporation Methods and compositions for treating cardiovascular disorders
WO2011150338A1 (en) 2010-05-27 2011-12-01 Zafgen Corporation Methods of treating obesity
US20120020647A1 (en) 2010-07-21 2012-01-26 Rovi Technologies Corporation Filtering repeated content
KR20130043207A (ko) 2010-07-22 2013-04-29 자프겐 인크. 트리시클릭 화합물 및 이의 제조 및 사용 방법
US8428080B2 (en) 2010-09-16 2013-04-23 Apple Inc. Method to control reconfiguration of multiple radio access bearers in a wireless device
AU2011316550A1 (en) 2010-10-12 2013-05-02 Zafgen, Inc Sulphonamide compounds and methods of making and using same
PH12013500934A1 (en) 2010-11-09 2022-10-24 Zafgen Inc Crystalline solids of a metap-2 inhibitor and methods of making and using same
US20140073691A1 (en) 2010-11-10 2014-03-13 Zafgen, Inc. Methods and composition for Treating Thyroid Hormone Related Disorders
US20130316994A1 (en) 2010-11-29 2013-11-28 Zafgen, Inc. Methods of Reducing Risk of Hepatobiliary Dysfunction During Rapid Weight Loss with METAP-2 Inhibitors
WO2012103333A1 (en) 2011-01-26 2012-08-02 Zafgen Corporation Tetrazole compounds and methods of making and using same
PH12013502261A1 (en) * 2011-05-06 2022-10-26 Zafgen Inc Partially saturated tricyclic compounds and methods of making and using same
KR20140053013A (ko) 2011-05-06 2014-05-07 자프겐 인크. 삼환식 설폰아마이드 화합물 그리고 그의 제조방법 및 그를 이용하는 방법
AU2012253760B2 (en) 2011-05-06 2016-02-04 Zafgen, Inc. Tricyclic pyrazole sulfonamide compounds and methods of making and using same
WO2013033430A1 (en) 2011-09-02 2013-03-07 Wake Forest School Of Medicine Targeted delivery and prodrug designs for platinum-acridine anti-cancer compounds and methods thereof
US9868717B2 (en) 2012-11-05 2018-01-16 Zafgen, Inc. Tricyclic sulphonamide compounds and methods of making and using same
CN104870433A (zh) 2012-11-05 2015-08-26 扎夫根股份有限公司 三环化合物及其制备方法和用途

Also Published As

Publication number Publication date
CA2861381A1 (en) 2013-07-25
US9440943B2 (en) 2016-09-13
JP2015509102A (ja) 2015-03-26
EP2804856A1 (en) 2014-11-26
WO2013109735A1 (en) 2013-07-25
BR112014017780A2 (enExample) 2017-06-20
CN104169268A (zh) 2014-11-26
EP2804856B1 (en) 2017-03-15
US20150119456A1 (en) 2015-04-30
BR112014017780A8 (pt) 2017-07-11
AU2013209719A1 (en) 2014-08-07
KR20140112566A (ko) 2014-09-23

Similar Documents

Publication Publication Date Title
MX343687B (es) Compuestos sulfonamida tricíclica y métodos para su fabricación y uso.
MX2014008705A (es) Compuestos tricíclicos de sulfona y métodos para elaborarlos y utilizarlos.
MX343688B (es) Compuestos tricíclicos de sulfonamida y pirazolo y métodos para su fabricación y uso.
PH12013502261A1 (en) Partially saturated tricyclic compounds and methods of making and using same
MX2014008706A (es) Compuestos tricíclicos de sulfonamida y métodos para elaborarlos y usarlos.
MX339201B (es) Compuestos de sulfonamida y métodos para elaborarlos y usarlos.
MX344238B (es) Compuestos de tetrazol y métodos para preparar y usar los mismos.
MX343135B (es) Compuestos de tipo fumagilol y métodos de realización y uso de los mismos.
MX356755B (es) Compuestos de tipo fumagilol y metodos para su elaboración y uso.
SG10201808102WA (en) Bicyclic heterocycle compounds and their uses in therapy
MX2013011908A (es) Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank.
TN2015000278A1 (en) Autotaxin inhibitors
BR112013001613A2 (pt) compostos tricíclicos e métodos para fazer e usar os mesmos.
MX2020010535A (es) Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide.
PH12013501600A1 (en) Novel heterocyclic derivatives
GB201209613D0 (en) New compounds
GB201118656D0 (en) New compounds
MX366899B (es) Nuevos compuestos.
PH12018500315A1 (en) Fumagillol heterocyclic compounds and methods of making and using same
MX2015005732A (es) Compuestos tricíclicos y métodos para hacer y utilizar los mismos.
GB201213484D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods of using the same
MX2013002118A (es) 2-oxi-quinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.
MX2016006544A (es) Witanolidos utiles para el tratamiento de enfermedades neurodegenerativas.
MX2015005733A (es) Compuestos triciclicos para usarse en el tratamiento y/o control de obesidad.
GB201115977D0 (en) Neurodevelopmental disorders